PURPOSE: MicroRNA (miRNA) is a new class of small, noncoding RNA. The purpose of this study was to determine if miRNAs are differentially expressed in hepatocellular carcinoma (HCC). EXPERIMENTAL DESIGN: More than 200 precursor and mature miRNAs were profiled by real-time PCR in 43 and 28 pairs of HCC and adjacent benign liver, respectively, and in normal liver specimens. RESULTS: Several miRNAs including miR-199a, miR-21, and miR-301 were differentially expressed in the tumor compared with adjacent benign liver. A large number of mature and precursor miRNAs were up-regulated in the adjacent benign liver specimens that were both cirrhotic and hepatitis-positive compared with the uninfected, noncirrhotic specimens (P < 0.01). Interestingly, all of the miRNAs in this comparison had increased expression and none were decreased. The expression of 95 randomly selected mRNAs was not significantly altered in the cirrhotic and hepatitis-positive specimens, suggesting a preferential increase in the transcription of miRNA. Comparing the miRNA expression in the HCC tumors with patient's survival time revealed two groups of patients; those with predominantly lower miRNA expression and poor survival and those with predominantly higher miRNA expression and good survival (P < 0.05). A set of 19 miRNAs significantly correlated with disease outcome. A number of biological processes including cell division, mitosis, and G(1)-S transition were predicted to be targets of the 19 miRNAs in this group. CONCLUSION: We show that a global increase in the transcription of miRNA genes occurs in cirrhotic and hepatitis-positive livers and that miRNA expression may prognosticate disease outcome in HCC.
PURPOSE: MicroRNA (miRNA) is a new class of small, noncoding RNA. The purpose of this study was to determine if miRNAs are differentially expressed in hepatocellular carcinoma (HCC). EXPERIMENTAL DESIGN: More than 200 precursor and mature miRNAs were profiled by real-time PCR in 43 and 28 pairs of HCC and adjacent benign liver, respectively, and in normal liver specimens. RESULTS: Several miRNAs including miR-199a, miR-21, and miR-301 were differentially expressed in the tumor compared with adjacent benign liver. A large number of mature and precursor miRNAs were up-regulated in the adjacent benign liver specimens that were both cirrhotic and hepatitis-positive compared with the uninfected, noncirrhotic specimens (P < 0.01). Interestingly, all of the miRNAs in this comparison had increased expression and none were decreased. The expression of 95 randomly selected mRNAs was not significantly altered in the cirrhotic and hepatitis-positive specimens, suggesting a preferential increase in the transcription of miRNA. Comparing the miRNA expression in the HCC tumors with patient's survival time revealed two groups of patients; those with predominantly lower miRNA expression and poor survival and those with predominantly higher miRNA expression and good survival (P < 0.05). A set of 19 miRNAs significantly correlated with disease outcome. A number of biological processes including cell division, mitosis, and G(1)-S transition were predicted to be targets of the 19 miRNAs in this group. CONCLUSION: We show that a global increase in the transcription of miRNA genes occurs in cirrhotic and hepatitis-positive livers and that miRNA expression may prognosticate disease outcome in HCC.
Authors: Eun Joo Lee; Yuriy Gusev; Jinmai Jiang; Gerard J Nuovo; Megan R Lerner; Wendy L Frankel; Daniel L Morgan; Russell G Postier; Daniel J Brackett; Thomas D Schmittgen Journal: Int J Cancer Date: 2007-03-01 Impact factor: 7.396
Authors: Yuriy Gusev; Thomas D Schmittgen; Megan Lerner; Russell Postier; Daniel Brackett Journal: BMC Bioinformatics Date: 2007-11-01 Impact factor: 3.169
Authors: Andrew Feber; Liqiang Xi; Arjun Pennathur; William E Gooding; Santhoshi Bandla; Maoxin Wu; James D Luketich; Tony E Godfrey; Virginia R Litle Journal: Ann Thorac Surg Date: 2011-03-21 Impact factor: 4.330
Authors: Giacomo Diaz; Marta Melis; Ashley Tice; David E Kleiner; Lopa Mishra; Fausto Zamboni; Patrizia Farci Journal: Int J Cancer Date: 2013-03-16 Impact factor: 7.396
Authors: Michael T Eadon; Alexander Jacob; Patrick N Cunningham; Richard J Quigg; Joe G N Garcia; Jessy J Alexander Journal: Immunology Date: 2014-11 Impact factor: 7.397
Authors: Pascal Pineau; Stefano Volinia; Katherine McJunkin; Agnès Marchio; Carlo Battiston; Benoît Terris; Vincenzo Mazzaferro; Scott W Lowe; Carlo M Croce; Anne Dejean Journal: Proc Natl Acad Sci U S A Date: 2009-12-15 Impact factor: 11.205